<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">368206</article-id><article-id pub-id-type="doi">10.18565/pharmateca.2025.9.152-157</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Oncology</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Онкология</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of perfusion computed tomography in the diagnosis of kidney cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Роль перфузионной компьютерной томографии в диагностике рака почки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1103-4532</contrib-id><name-alternatives><name xml:lang="en"><surname>Khasigov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Хасигов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alan_hasigov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-2173-8384</contrib-id><name-alternatives><name xml:lang="en"><surname>Tebiyev</surname><given-names>V. T.</given-names></name><name xml:lang="ru"><surname>Тебиев</surname><given-names>В. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tebiyevv@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Timoshenkova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Тимошенкова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>colorsit21@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">North Ossetian State Medical Academy</institution></aff><aff><institution xml:lang="ru">Северо-Осетинская государственная медицинская академия</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-12-29" publication-format="electronic"><day>29</day><month>12</month><year>2025</year></pub-date><volume>32</volume><issue>9</issue><fpage>152</fpage><lpage>157</lpage><history><date date-type="received" iso-8601-date="2026-01-18"><day>18</day><month>01</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО «Бионика Медиа»</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.rcsi.science/2073-4034/article/view/368206">https://journals.rcsi.science/2073-4034/article/view/368206</self-uri><abstract xml:lang="en"><p><bold>Background:</bold> Imaging methods such as ultrasound, computed tomography (CT), positron emission tomography, and magnetic resonance imaging (MRI) play a leading role in the detection of kidney tumors. Renal CT is the standard for diagnosing renal cell carcinoma (RCC). Digital data on perfusion CT (PCT) parameters for the tumor zone and healthy tissue allow to determine normalized «i» values for each RCC parameter (BF – blood flow, BV – blood volume, MTT – mean transit time, TTP – time to peak).</p> <p>Despite the long history of studying RCC, diagnostic methods, and imaging, CT and/or MRI do not have sufficient specificity. Based on the statistical analysis, PCT has great potential in diagnosing renal masses and may open new perspectives for optimizing surgical tactics due to its high information content in the differential diagnosis of benign and malignant renal masses.</p> <p><bold>Objective: </bold>Determination of the diagnostic value of PCT in optimizing surgical treatment tactics and assessing the functional capacity of the renal parenchyma in RCC.</p> <p><bold>Materials and methods: </bold>The study analyzed data from 119 patients (58.3 ± 12.6 years) with a confirmed diagnosis of RCC who underwent PCT before treatment and at 1 and 3 months after the start of therapy. Four perfusion parameters were evaluated for the diagnosis of RCC: BF, BV, MTT, and TTP.</p> <p><bold>Results:</bold> According to the analysis, 1 month after of treatment, patients (n=45) responding to therapy showed a decrease in BF and BV in tumor tissue (p&lt;0.01). In the group of non-responders (n=34), changes in perfusion parameters were non-significant (p&gt;0.05). In patients responding to therapy after 3 months, perfusion parameters continued to decline. The mean BF was 85.2±15.3 ml/100 g/min, and BV was 10.7±2.1 ml/100 g.</p> <p><bold>Conclusion:</bold> PCT has great potential and opens new perspectives in the diagnosis, assessment, and surgical management of RCC.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование:</bold> Ведущая роль в выявлении образований почек отводится методам медицинской визуализации, таким как ультразвуковое исследование (УЗИ), компьютерная томография (КТ), позитронно-эмиссионная томография, магнитно-резонансная томография (МРТ). КТ почек – стандарт диагностики почечно-клеточного рака (ПКР). Цифровые данные параметров перфузионной КТ (ПКТ) зоны опухоли и здоровой ткани позволяют определить нормализованные значения «и» каждого параметра ПКТ (BF – кровоток, BV – объем крови, MTT – среднее время прохождения, TTP – время до достижения пика).</p> <p>Несмотря на многолетнюю историю изучения ПКР, методов диагностики и медицинской визуализации, КТ и/или МРТ не обладают достаточной специфичностью. По результатам статистического анализа ПКТ обладает большим потенциалом в диагностике образований почек и может открывать новые перспективы в оптимизации хирургической тактики за счёт высокой информативности при дифференциальной диагностике доброкачественных и злокачественных образований почек.</p> <p><bold>Цель исследования:</bold> Определить диагностическую ценность ПКТ в оптимизации хирургической тактики лечения и оценки функциональной способности почечной паренхимы при ПКР.</p> <p><bold>Материалы и методы:</bold> В исследовании проанализированы данные 119 пациентов (58,3±12,6 года) с подтвержденным диагнозом ПКР, которым выполнялась ПКТ до начала лечения, через 1 и 3 месяца после начала терапии. Оценивались 4 показателя перфузии для диагностики ПКР: BF, BV, MTT и TTP.</p> <p><bold>Результаты: </bold>По результатам проведённого анализа, через 1 месяц лечения у пациентов (n=45), отвечающих на терапию, отмечено снижение BF и BV в опухолевой ткани (p&lt;0,01). В группе пациентов, не отвечающих на терапию (n=34), изменения перфузионных параметров были незначимыми (p&gt;0,05). У пациентов, отвечающих на терапию через 3 месяца, продолжалось снижение перфузионных параметров. При этом средний BF составил 85,2±15,3 мл/100 г/мин, а BV – 10,7±2,1 мл/100 г.</p> <p><bold>Заключение: </bold>ПКТ обладает большим потенциалов и открывает новые перспективы в диагностике, оценке и хирургической тактике ПКР.</p></trans-abstract><kwd-group xml:lang="en"><kwd>renal cell carcinoma</kwd><kwd>perfusion computed tomography</kwd><kwd>perfusion parameters</kwd><kwd>blood flow volume</kwd><kwd>blood volume</kwd><kwd>time to peak</kwd><kwd>mean transit time</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>почечно-клеточного рак</kwd><kwd>перфузионная компьютерная томография</kwd><kwd>перфузионные параметры</kwd><kwd>объем кровотока</kwd><kwd>объем крови</kwd><kwd>время до пика</kwd><kwd>среднее транзитное время</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена без спонсорской поддержки.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gigli F., Zattoni F., Zamboni G., et al. Correlation between pathologic features and perfusion CT of renal cancer: a feasibility study. Urologia. 2010;77:223–31.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mazzei F.G., Mazzei M.A., Cioffi Squitieri N., et al. CT perfusion in the characterisation of renal lesions: an added value to multiphasic CT. Biomed Res Int. 2014;2014:135013.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chandarana H., Rosenkrantz A.B., Mussi T.C., et al. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer. Radiology. 2012;265:790–8. https://doi.org/10.1148/radiol.12111281</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chen Y., Zhang J., Dai J., et al. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging. 2010;35:622–8. https://doi.org/10.1007/s00261-009-9565-0</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zhang J., Wang R., Lou H., et al. Functional computed tomographic quantification of angiogenesis in rabbit VX2 soft-tissue tumor before and after interventional therapy. J Comput Assist Tomogr. 2008;32:697–705. https://doi.org/10.1097/RCT.0b013e31815b7dcf</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Reiner C.S., Roessle M., Thiesler T., et al. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers. Invest Radiol. 2013;48:183–91. https://doi.org/10.1097/RLI.0b013e31827c63a3</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bianchi M., Sun M., Jeldres C., et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973–80. Doi: 10.1093/annonc/mdr362</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bektas C.T., et al. Clear cell renal cell carcinoma: machine learning-based quantitative computed tomography texture analysis for prediction of fuhrman nuclear grade. Eur Radiol. 2019;29(3):1153–63. https://doi.org/10.1007/s00330-018-5698-2</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Erdim C., et al. Prediction of benign and malignant solid renal masses: machine learning-based CT texture analysis. Acad Radiol. 2020;27(10):1422–9. https://doi.org/10.1016/j.acra.2019.12.015</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bellin M.F., Roy C., Kinkel K., Dupas B. Magnetic resonance imaging of renal masses: Diagnostic approach. Eur Radiol. 2005;15(11):2231–41.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sun H. Classification of small renal masses based on CT images and machine learning algorithms. MS Thesis, Univ. of Turku. 2018.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kocak B., et al. Textural differences between renal cell carcinoma subtypes: machine learning-based quantitative computed tomography texture analysis with independent external validation. Eur J Radiol. 2018;107:149–57. https://doi.org/10.1016/j.ejrad.2018.08.014</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hodgdon T., et al. Can quantitative CT texture analysis be used to differentiate fat-poor renal angiomyolipoma from renal cell carcinoma on unenhanced CT images? Radiology. 2015;276(3):787–96. https://doi.org/10.1148/radiol.2015142215</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Jewett M.A., Mattar K., Basiuk J., Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011;60(1):39. https://doi.org/10.1016/j.eururo.2011.03.030</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ломоносова Е.В., Гольбиц А.Б., Рубцова Н.А. и др. Перфузионная компьютерная томография в диагностике заболеваний почек (обзор литературы). Медицинская визуализация. 2023;27(2):85–98. [Lomonosova E.V., Golbitz A.B., Rubtsova N.A., et al. Perfusion computed tomography in the diagnosis of kidney diseases (literature review). Meditsinskaya vizualizatsiya. 2023;27(2):85–98. (In Russ.)].</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Рубцова Н.А., Гольбиц А.Б., Крянева Е.В. и др. Роль КТ-перфузии в диагностике солидных опухолей почек. Лучевая диагностика и терапия. 2021;12(2):70–8. [Rubtsova N.A., Golbitz A.B., Kryaneva E.V., et al. The role of CT perfusion in the diagnosis of solid kidney tumors. Luchevaya diagnostika i terapiya. 2021;12(2):70–8. (In Russ.)].</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang Y., et al. Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma. Abdom Radiol. 2019;44:3370–6. https://doi.org/10.1007/s00261-019-02087-z</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Chen C., et al. Study of 320-Slice dynamic volume CT perfusion in different pathologic types of kidney tumor: preliminary results. PLoS One. 2014;9(1):e85522. https://doi.org/10.1371/journal.pone.0085522</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Das C.J., Thingujam U., Panda A., et al. Perfusion computed tomography in renal cell carcinoma. World J Radiol. 2015;7(7):170–9. https://doi.org/Doi: 10.4329/wjr.v7.i7.170</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Garcia-Figueiras R., et al. CT Perfusion in Oncologic Imaging: A Useful Tool. AJR. 2000. 2013. https://doi.org/10.2214/AJR.11.8476</mixed-citation></ref></ref-list></back></article>
